AU2004229237B2 - Use of SLURP-1 for treating diseases related to acetylcholine receptors dysfunction - Google Patents

Use of SLURP-1 for treating diseases related to acetylcholine receptors dysfunction Download PDF

Info

Publication number
AU2004229237B2
AU2004229237B2 AU2004229237A AU2004229237A AU2004229237B2 AU 2004229237 B2 AU2004229237 B2 AU 2004229237B2 AU 2004229237 A AU2004229237 A AU 2004229237A AU 2004229237 A AU2004229237 A AU 2004229237A AU 2004229237 B2 AU2004229237 B2 AU 2004229237B2
Authority
AU
Australia
Prior art keywords
slurp
acetylcholine receptor
subject
effective amount
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004229237A
Other languages
English (en)
Other versions
AU2004229237A1 (en
Inventor
Daniel Bertrand
Fabrice Chimienti
Ronald Hogg
Daniel Hohl
Marcel Huber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Publication of AU2004229237A1 publication Critical patent/AU2004229237A1/en
Assigned to APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. reassignment APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. Amend patent request/document other than specification (104) Assignors: Applied Research Systems ARS Holding N.V., Has no value - Entry Incomplete
Assigned to LABORATOIRES SERONO SA reassignment LABORATOIRES SERONO SA Request for Assignment Assignors: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Assigned to MERCK SERONO SA reassignment MERCK SERONO SA Alteration of Name(s) of Applicant(s) under S113 Assignors: LABORATOIRES SERONO S.A.
Application granted granted Critical
Publication of AU2004229237B2 publication Critical patent/AU2004229237B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
AU2004229237A 2003-04-16 2004-04-16 Use of SLURP-1 for treating diseases related to acetylcholine receptors dysfunction Ceased AU2004229237B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46341803P 2003-04-16 2003-04-16
US60/463,418 2003-04-16
PCT/IB2004/001716 WO2004091646A2 (en) 2003-04-16 2004-04-16 Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction

Publications (2)

Publication Number Publication Date
AU2004229237A1 AU2004229237A1 (en) 2004-10-28
AU2004229237B2 true AU2004229237B2 (en) 2009-06-04

Family

ID=33300074

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004229237A Ceased AU2004229237B2 (en) 2003-04-16 2004-04-16 Use of SLURP-1 for treating diseases related to acetylcholine receptors dysfunction

Country Status (11)

Country Link
US (2) US7135454B2 (ja)
EP (1) EP1613341B1 (ja)
JP (1) JP4891065B2 (ja)
AT (1) ATE494903T1 (ja)
AU (1) AU2004229237B2 (ja)
CA (1) CA2520029C (ja)
DE (1) DE602004031003D1 (ja)
ES (1) ES2359408T3 (ja)
IL (1) IL171384A (ja)
NO (1) NO337494B1 (ja)
WO (1) WO2004091646A2 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1786473A4 (en) * 2004-08-11 2008-11-19 Cedars Sinai Medical Center TREATMENT OF PARKINSON DISEASE AND RELATED DISEASES
US7858590B2 (en) * 2005-08-11 2010-12-28 Cedars-Sinai Medical Center Treatment of parkinson's disease and related disorders
US20080221013A1 (en) * 2006-09-02 2008-09-11 Julie Miwa Neurobiological compositions
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
RU2453602C2 (ru) * 2010-08-19 2012-06-20 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pЕТ22b(+)/SLURP-1, КОДИРУЮЩАЯ БЕЛОК SLURP-1, И ШТАММ БАКТЕРИЙ Escherichia coli BL21(DE3)/pET22b(+)/SLURP-1-ПРОДУЦЕНТ БЕЛКА SLURP-1 ЧЕЛОВЕКА
NZ609761A (en) 2010-09-23 2015-10-30 Abbvie Bahamas Ltd Monohydrate of an azaadamantane derivative
WO2012167214A1 (en) 2011-06-03 2012-12-06 Ophidion Inc. Compositions and methods for transport across the blood brain barrier
US9132193B2 (en) 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
EP2740485B1 (en) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 for use in the treatment of ocular diseases
CN114601915B (zh) * 2022-03-25 2023-04-07 四川大学华西医院 Slurp1蛋白在制备预防或治疗皮肤弹性纤维疾病的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056810A2 (de) * 1997-06-09 1998-12-17 Forssmann Wolf Georg Humanes protein lus-i, seine herstellung und verwendung
US5908827A (en) * 1992-12-22 1999-06-01 Applied Research Systems Ars Holding N.V. Protein from urine named component B

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5298604A (en) 1992-07-27 1994-03-29 Sloane Nathan H Parital primary amino acid sequence of the antineoplastic protein (ANUP); a cytokine present in granulocytes
DK0895478T3 (da) 1996-04-24 2003-06-23 Applied Research Systems Bestanddel B som ardanner
CA2336773C (en) 1998-07-09 2009-12-15 Applied Research Systems Ars Holding N.V. Component b as angiogenic agent in combination with human growth factors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908827A (en) * 1992-12-22 1999-06-01 Applied Research Systems Ars Holding N.V. Protein from urine named component B
WO1998056810A2 (de) * 1997-06-09 1998-12-17 Forssmann Wolf Georg Humanes protein lus-i, seine herstellung und verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FISCHER J et al. Human Molecular Genetics. 2001. 10(8): 875-880 *

Also Published As

Publication number Publication date
NO20055309D0 (no) 2005-11-10
CA2520029A1 (en) 2004-10-28
CA2520029C (en) 2014-07-15
ES2359408T3 (es) 2011-05-23
US7135454B2 (en) 2006-11-14
JP2006523678A (ja) 2006-10-19
IL171384A (en) 2010-12-30
DE602004031003D1 (de) 2011-02-24
NO337494B1 (no) 2016-04-25
NO20055309L (no) 2006-01-16
US20050004025A1 (en) 2005-01-06
EP1613341B1 (en) 2011-01-12
US20070219130A1 (en) 2007-09-20
ATE494903T1 (de) 2011-01-15
US7691808B2 (en) 2010-04-06
WO2004091646A2 (en) 2004-10-28
EP1613341A2 (en) 2006-01-11
JP4891065B2 (ja) 2012-03-07
AU2004229237A1 (en) 2004-10-28
WO2004091646A3 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
US7691808B2 (en) Use of Slurp-1 for treating diseases related to acetylcholine receptor dysfunction
Stout et al. The synaptic vesicle glycoprotein 2: structure, function, and disease relevance
ES2341842T3 (es) Bloqueo del crecimiento axonal mediado por el receptor de nogo.
US6696303B2 (en) Identifying substances using cells that express p75NTR
CN105641694B (zh) 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
JP2008500266A (ja) Ａｍｐａ受容体エンドサイトーシスの阻害剤を用いた神経細胞反応のモジュレート方法
US20230414717A1 (en) Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
EP1339742A2 (en) Human protein differentially expressed in alzheimer's disease's brain
Thompson et al. Suppression of TNF receptor-1 signaling in an in vitro model of epileptic tolerance
Mishima et al. Ameliorative effect of vasopressin-(4–9) through vasopressin V1A receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze
US5731410A (en) Peptide for blocking autoantibody-evoked activation of glutamate receptor type 3 (GLUR3)
KR19990007893A (ko) 중추신경계（ｃｎｓ） 축삭 성장 모듈레이터, 이를 구현 및 사용하는 조성물, 세포 및 방법
US20170176417A1 (en) Method and Pharmaceutical Composition for Use in the Treatment of Neurodegenerative Disorders
US20130065825A1 (en) Compositions and Methods for Delaying Senescence or Cell Death in Neurons
DE60105609T2 (de) Metabolismuskontrolle mittels zusamensetzungen des humanen 2-oxoglutarat-trägers
Chen et al. Expression of synaptosomal-associated protein-25 in the rat brain after subarachnoid hemorrhage
US20170137470A1 (en) Kv1.3 Potassium Channel Antagonists
AU2001249207B2 (en) Method for reducing allergen-induced airway hyperresponsiveness
US20100196376A1 (en) Method for reducing allergen-induced airway hyperresponsiveness
KR20060059257A (ko) 도파민 수용체를 사용한 근육 질량 또는 기능의 조절을위한 화합물의 동정 방법
Gahring et al. Neurodegenerative disease and the neuroimmunobiology of glutamate receptors
O'Malley The role of sodium channel α and β subunits in myelinating glia and demyelinating disorders
Dai Regulation of transglutaminase by 5-HT2A receptor signaling and calmodulin
US20090304698A1 (en) Modulation of ovulation
CA2221391A1 (en) Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

Free format text: FORMER NAME: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V., HAS NO VALUE - ENTRY INCOMPLETE

TH Corrigenda

Free format text: IN VOL 20, NO 15, PAGE(S) 1439 UNDER THE HEADING CHANGE OF NAMES(S) OF APPLICANT(S), SECTION 104 - 2004 UNDER THE NAME APPLIED RESEARCH SYSTEMS ARS HOLDING N.V., HAS NO VALUE - ENTRY INCOMPLETE, APPLICATION NUMBER 2004229237, CORRECT THE NAME TO APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

PC1 Assignment before grant (sect. 113)

Owner name: LABORATOIRES SERONO SA

Free format text: FORMER APPLICANT(S): APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired